Beta thalassaemia

Haemoglobin — the molecule that fills red cells and carries oxygen — is built from two pairs of protein chains: alpha and beta. Beta thalassaemia is what happens when the gene for the beta chain carries variants that reduce its output (written β+) or silence it entirely (β0). The consequences run beyond a simple shortage. Unpaired alpha chains, left without beta partners, clump inside developing red cells and destroy many of them before they ever leave the marrow — a process called ineffective erythropoiesis — while the cells that do emerge are small, pale and short-lived. The marrow responds to the anaemia by expanding massively, the spleen enlarges as it clears defective cells, and the gut absorbs extra iron in a futile attempt to help: three facts that explain most of the untreated disease’s features.

How much beta-globin remains determines the clinical form. Carriers of one variant — thalassaemia minor or trait — are essentially healthy, with mild laboratory changes easily mistaken for iron deficiency; their significance is reproductive, since two carrier parents can have a severely affected child. Two significant variants produce disease along a spectrum that medicine now labels by need rather than by name: transfusion-dependent thalassaemia (the classical thalassaemia major), in which survival depends on regular transfusion from infancy or early childhood; and non-transfusion-dependent thalassaemia (roughly the classical intermedia), in which haemoglobin is low but liveable, with transfusions needed only intermittently — a form whose complications, particularly iron loading from the gut and thrombosis after splenectomy, are easy to underestimate.

The disease follows historical malaria geography — the Mediterranean, the Middle East, North Africa, South and Southeast Asia — because carrying one variant conferred some protection against malaria; migration has since made it global. That geography matters practically: the countries this platform serves include some with the world’s deepest thalassaemia treatment experience, and some of the world’s longest-running carrier-screening programmes.

Care in modern thalassaemia is a lifetime relationship with a specialist day unit — the room where transfusions happen every few weeks is, for many families, as familiar as a school. The best programmes are explicitly multidisciplinary: haematology at the centre, with cardiology, endocrinology, hepatology, fertility and psychology in structured orbit, because the disease’s modern challenges live in exactly those clinics. Transition from paediatric to adult services — the point where adherence historically slips — is handled as a process, not a birthday. When families compare treatment options across borders, this architecture is what they are really comparing: the drugs are global commodities; the coordination is not.

Thalassaemia minor usually looks like nothing at all: mild anaemia on a blood test, small red cells, a person who feels well. It surfaces most often when routine tests are mistaken for iron deficiency, or during pregnancy screening — which is exactly when identifying it matters, for partner testing. A recurring real-world confusion deserves its sentence: trait is often mislabelled “mild anaemia” and treated for years with iron that cannot help and may quietly harm — any small-cell anaemia that fails to respond to a proper course of iron has earned haemoglobin analysis, not a repeat prescription.

Transfusion-dependent disease declares itself in infancy, typically between six months and two years as fetal haemoglobin — which needs no beta chains — fades away. The baby becomes pale, feeds poorly, tires, fails to gain weight and length as expected; the abdomen swells as liver and spleen enlarge; jaundice may tinge the eyes. Untreated or under-treated, the expanding marrow begins to reshape growing bone — prominent cheekbones and skull changes described in every textbook — while growth stalls and infections recur. These classical features are now, in well-resourced care, features of the PAST: a child transfused adequately from diagnosis grows and develops essentially normally, and the visible disease disappears into a transfusion schedule. Where the features still appear, they are a signal of under-treatment, not an inevitability of the disease.

Non-transfusion-dependent thalassaemia occupies the middle: chronic moderate anaemia with fatigue and reduced stamina, an enlarged spleen, gallstones from chronic red cell turnover, sometimes leg ulcers or bone changes appearing in adolescence or adulthood. Its symptoms creep rather than announce, and its iron overload — absorbed silently through the gut over decades — can injure organs before anyone feels ill, which is why this “milder” form still belongs under specialist follow-up.

In adults with established transfusion-dependent disease, new symptoms usually point at iron: heart rhythm disturbance or breathlessness (cardiac iron), diabetes symptoms (pancreatic iron), delayed puberty or fertility problems (pituitary iron). The symptom list of modern thalassaemia, in other words, is largely the symptom list of iron overload — the enemy the whole management system is built to hold back.

Beta thalassaemia is caused by variants in the HBB gene on chromosome 11, which encodes the beta-globin chain. Hundreds of variants are known, ranging from those that abolish output entirely (β0) to those that merely reduce it (β+); the combination a person inherits — one from each parent — largely sets the severity, though modifiers such as co-inherited alpha thalassaemia or a persistent ability to make fetal haemoglobin can soften the picture considerably. This is why two children with “the same disease” can need different treatment, and why genetic reports quote the specific variants rather than just the diagnosis.

The inheritance is autosomal recessive and worth stating precisely, because family planning turns on it. A carrier (trait) has one variant: healthy, but able to pass it on. When both parents are carriers, each pregnancy has a one-in-four chance of a child with two variants — severe disease — a two-in-four chance of a carrier, and a one-in-four chance of neither. Carrier state is common in populations from the historical malaria belt, and marrying within a community where the trait is frequent raises the chance that both partners carry it — the demographic fact behind the premarital and antenatal screening programmes that countries such as Cyprus, Italy, Greece, Türkiye and Iran have run for decades, some of which have reduced new severe births dramatically.

Related compound conditions matter in the same regions: haemoglobin E combined with beta thalassaemia (HbE/β-thalassaemia) is a major cause of transfusion-dependent disease in South and Southeast Asia, and sickle-beta thalassaemia behaves largely as sickle cell disease. A complete diagnosis therefore names both variants — information a transplant centre, and a genetic counsellor, will each ask for.

Alpha thalassaemia, the sibling condition, deserves a boundary note: it involves different genes (the alpha chains), its own spectrum from silent carriage to transfusion dependence, and frequent CO-inheritance with beta variants that modifies severity in both directions. Laboratories in high-prevalence regions type both routinely; families comparing results across relatives should compare gene names, not just the word “thalassaemia”.

For inheriting the disease, the risk factors are ancestry and parentage, not lifestyle: family origins in the Mediterranean, Middle East, North Africa, South Asia or Southeast Asia raise carrier probability, and two carrier parents create the one-in-four risk each pregnancy. Consanguineous marriage within high-carrier communities raises the chance both partners carry a variant. None of this involves fault; it is population genetics.

For complications in someone who has the disease, the risk factors are largely about care: transfusion adequacy, chelation adherence and monitoring access predict outcomes more strongly than the underlying genotype in most modern series. Irregular transfusion risks growth failure and marrow expansion; irregular chelation risks the cardiac and endocrine iron injuries; splenectomy adds lifelong infection and thrombosis risks that must be actively managed. Hepatitis acquired from transfusion belongs to history in screened blood supplies but remains a screening point in patients transfused decades ago or in under-resourced systems.

One modifiable amplifier deserves its line: malaria itself, in regions where both persist, hits thalassaemic patients harder through haemolysis and splenic stress — prevention measures and prompt treatment carry extra weight for affected travellers and residents, and pre-travel clinic advice should hear the word thalassaemia explicitly.

Thalassaemia is classified less by a severity ladder than by clinical form — defined, in modern practice, by what the person needs. The genotype underneath (β0/β0, β+/β0, β+/β+, HbE/β) influences but does not dictate the form.

Diagnosis begins with the blood count and film: small (microcytic), pale red cells with characteristic shapes, out of proportion to any iron deficiency — and, in the severe forms, marked anaemia with signs of vigorous but futile marrow effort. Haemoglobin analysis (electrophoresis or HPLC) makes the working diagnosis by quantifying the haemoglobin fractions: raised HbA2 marks the beta trait; absent or minimal adult HbA with high fetal HbF marks severe beta disease; HbE and other variants declare themselves on the same trace. DNA testing of the HBB gene then names the exact variants — increasingly standard everywhere, and essential before prenatal counselling, before gene therapy, and useful before transplant. Family studies of parents and siblings complete the picture and, in the same blood draw, can begin HLA typing of siblings: in a disease curable by matched-sibling transplant, knowing early whether a matched sibling exists shapes years of planning.

Monitoring in established disease is a discipline of its own, because modern thalassaemia care is essentially the management of iron. Serum ferritin, checked at every clinic visit, gives the rough trend cheaply. MRI has transformed precision: T2 cardiac MRI measures iron in the heart — the iron that kills — and R2/T2 liver MRI measures liver iron concentration, replacing biopsy for most purposes; both are repeated on a schedule, typically annually, and chelation is steered by their results. Around the iron axis sit the annual organ reviews: endocrine testing (glucose, thyroid, growth and puberty assessment, gonadal function), cardiac review, liver enzymes and hepatitis serology, bone density, eye and hearing checks on certain chelators, and alloantibody screening to keep transfusions compatible. It is a heavy calendar — and it is precisely this calendar, applied consistently, that turned thalassaemia from a childhood disease into an adult one.

Two practical notes on the tests themselves. Cardiac T2 MRI needs no contrast and takes minutes inside a standard scan — its scarcity in some regions is about scanner software and trained readers, not exotic hardware, and asking where the nearest T2-capable centre is counts among the most useful questions a family can put to a clinic. And ferritin, the everyday number, is honest about trends but easily distorted in single readings by infection or inflammation — clinics read its slope across visits, and so should families keeping their own log, which many of the best-organised do.

The values a thalassaemia family hears constantly, and what each is actually saying.

The complication that shaped thalassaemia’s history is transfusional iron overload. Every unit of blood delivers iron the body cannot excrete; untreated, it deposits in the heart (rhythm disturbance and heart failure — historically the leading cause of death, now much reduced where MRI-guided chelation is available), the liver (fibrosis and cirrhosis), and the endocrine glands (diabetes, hypothyroidism, delayed puberty, short stature, infertility). Non-transfused patients load iron too — more slowly, through the gut — which is the trap of the “milder” form.

Beyond iron: the over-driven marrow of under-treated disease expands bone and can form masses of blood-forming tissue outside the marrow; the spleen can enlarge enough to worsen anaemia and consume platelets, sometimes leading to splenectomy — which itself creates lifelong vulnerability to overwhelming infection (managed with vaccination, standby antibiotics and the fever rule above) and a raised thrombosis risk, particularly in non-transfusion-dependent disease. Gallstones are common from chronic red cell turnover. Bone disease — osteoporosis and pain — affects many adults despite good care: expanded marrow, endocrine deficits and the disease itself all thin bone, so calcium–vitamin D adequacy, weight-bearing activity and periodic density scanning belong in adult care plans, with fracture-threshold treatment where indicated. Alloimmunisation, the development of antibodies against transfused red cells, complicates cross-matching over the years and argues for extended blood matching from the start. Pregnancy in thalassaemia deserves its own planning: it is now common and usually successful, but it needs pre-conception cardiac iron assessment and coordinated obstetric-haematology care.

Listing complications this way risks obscuring the headline: in a well-run modern programme, most of them are preventable or containable, and cohorts transfused and chelated to target now live long adult lives. The complication list is best read as a description of what the treatment calendar exists to prevent.

Beta thalassaemia is the textbook example of a disease preventable at the population level. Carrier testing — a simple blood count plus haemoglobin analysis — identifies trait cheaply and reliably; premarital and antenatal screening programmes, combined with genetic counselling and, where couples choose it, prenatal diagnosis or pre-implantation genetic testing, have reduced new severe births dramatically in several countries. For an individual from an at-risk community, the practical translation is one sentence: get tested before having children, and if you carry the trait, have your partner tested too. Trait itself needs no treatment — and one specific harm to avoid is being treated indefinitely with iron for a “mild anaemia” that iron will never fix.

For a person living with the disease, prevention means preventing the complications, and the levers are exactly the unglamorous ones the monitoring section lists: transfusing to target rather than to symptoms; taking chelation as prescribed — the single hardest and single most valuable habit in thalassaemia, since the drugs only work on the days they are taken; keeping the annual MRI and endocrine appointments even when life is busy and the person feels well; vaccination and antibiotic discipline after splenectomy; and pre-pregnancy planning rather than pregnancy surprises. Families add one more preventive act with lifelong reach: having young siblings HLA-typed early, so the curative option is known about years before it might be needed.

The standard of care for transfusion-dependent thalassaemia stands on two legs. The first is regular transfusion, typically every two to five weeks, keeping the pre-transfusion haemoglobin high enough to suppress the marrow’s harmful expansion — a target-driven strategy, not a rescue-driven one. The second is iron chelation therapy, begun once transfusional iron accumulates: deferoxamine by slow infusion (the original agent, still valuable), and the oral agents deferasirox and deferiprone, used alone or in combinations tailored to the organ pattern of iron on MRI — deferiprone having particular evidence for cardiac iron. Between them sit the supporting acts: extended-matched blood to limit alloimmunisation, splenectomy now used far more sparingly than historically, folic acid, endocrine replacement where deficits have developed, and bone protection.

One disease-modifying drug has joined recently: luspatercept, which improves the maturation of red cells and reduces transfusion burden in many adults with beta thalassaemia — a genuine addition for those it helps, though not a cure. Hydroxycarbamide raises fetal haemoglobin usefully in some non-transfusion-dependent and HbE/β patients.

The cures change the story rather than the schedule. Allogeneic stem cell transplantation — detailed in the next section — replaces the marrow’s faulty red cell factory with a donor’s and has cured thousands of patients over four decades, with its best results in young children transplanted from matched siblings before iron injury accumulates. And gene therapy has arrived: therapies that add a working beta-globin gene (betibeglogene autotemcel) or reactivate fetal haemoglobin through gene editing (exagamglogene autotemcel, a CRISPR-based therapy) have received regulatory approval in several jurisdictions and can achieve transfusion independence — using the patient’s own modified cells, so no donor and no graft-versus-host risk, at the price of chemotherapy conditioning, extremely limited availability and, at launch, some of the highest prices in medicine. For most of the world’s thalassaemia patients today, transplant remains the accessible cure; gene therapy is the direction of travel worth asking about, honestly labelled as such.

Daily management, from the patient’s side, compresses into a rhythm: the transfusion appointment every two to five weeks (a few hours, often arranged around school or work); the chelation habit — a nightly tablet or infusion whose entire value lives in its consistency; the annual scan-and-clinic block; and the ordinary life in between, which modern care intends to be genuinely ordinary — school, sport, careers, travel (with letters and supplies arranged for longer trips), marriage and, with planning, children. Units increasingly co-design schedules with patients precisely because a regimen that fits a life is the one that actually happens.

Thalassaemia is one of the oldest and best-established indications for stem cell transplantation in a non-cancer disease: the faulty organ is the marrow’s red cell production line, and replacing the marrow replaces the disease. The evidence base assembled over decades — much of it from centres in Italy and the Mediterranean world that pioneered the field — points to one consistent conclusion: results are best in young children, transplanted from an HLA-matched sibling, before iron overload and liver injury take hold. The historical Pesaro classification formalised exactly this, grading risk by liver size, fibrosis and chelation quality; its modern translation is simple — the earlier and the better-chelated, the better the outcome, which is why the transplant conversation belongs in the first years after diagnosis, not the last resort years.

The pathway follows the familiar shape with thalassaemia-specific accents. Donor first: matched sibling remains the gold standard — with the caveat that siblings are tested for thalassaemia themselves, since a carrier sibling CAN donate but an affected one cannot — while matched unrelated donors and, in experienced centres, haploidentical parents or siblings have expanded access substantially in the last decade. Conditioning is myeloablative but adapted; rejection is a particular concern because thalassaemic recipients have intact, transfusion-experienced immune systems, and protocols are built accordingly. Iron status is optimised before transplant where time allows, and — a detail families rarely expect — unloading continues AFTER a successful transplant, by simple venesection once transfusions stop, to clear the iron legacy of the transfused years.

For families considering treatment abroad — common in thalassaemia, given how unevenly transplant access maps onto where the disease is prevalent — the file a centre needs is: the genotype report naming both variants; the transfusion history and current regimen; the full iron picture (recent ferritin trend, cardiac T2*, liver iron MRI); infection serology; splenectomy status; and HLA typing of the patient and all full siblings. With that file, an experienced centre can give a family a real, individual answer about risk and timing — the answer this page deliberately does not pretend to give. The stem cell transplant guide covers the procedure; the living donation page covers what sibling donors are asked.

Two generations ago, severe beta thalassaemia was a fatal childhood disease. Today the outlook divides along a line drawn by access. Where transfusion is regular, blood is safe, chelation is MRI-guided and follow-up is kept, transfusion-dependent patients routinely reach middle age and beyond — cardiac deaths, once dominant, have fallen steeply in such cohorts — and where transplant is available young, a large majority of matched-sibling recipients are simply cured, growing up transfusion-free. Gene therapy’s early results add a second curative road whose long-term durability is still being written.

Where access fails — irregular blood supply, unaffordable chelation, no monitoring — the old natural history reasserts itself. That is the honest global picture, and it is why this disease, more than most on this platform, rewards organised care-seeking: the difference between outcomes is less about biology than about system. For an individual family, the practical outlook questions have concrete answers worth pursuing: what is the cardiac T2* now; is there a matched sibling; what would a transplant centre quote as risk at this age and iron load; and — if standard care continues — is the chelation plan one the patient can actually live with? A team that can answer those four questions can usually also deliver the good version of this disease’s story.

For the generation now growing up transfused and chelated to target — or transplanted young — the horizon questions have shifted from survival to quality: bone health, fertility support, career insurance questions in some systems, and the psychological weight of a lifelong schedule. Patient associations, several cited below, have grown into sophisticated sources of exactly this lived-experience knowledge, and connecting with one is a genuinely evidence-backed recommendation: adherence, and with it outcomes, measurably improves in supported patients.

And for the family reading this at diagnosis — usually over an infant — the compressed honest version: this is now a manageable disease with two curative exits; the first year’s job is establishing the transfusion rhythm and testing siblings; the first decade’s job is chelation habit and growth; and the decisions that most shape the life ahead (transplant timing above all) reward being asked EARLY, in calm clinic rooms, years before they are urgent. Families who pace it that way describe the disease as demanding but navigable — the version this page is written to make more common.